Glenview Capital Issues Statement on CVS Health

Rhea-AI Summary

Glenview Capital reported on its investment in CVS Health (NYSE: CVS), noting an 80% total return on shares purchased since May 2024. After healthy Q1 results and higher annual guidance, Glenview rebalanced in May 2026, selling 3.75 million shares while keeping CVS among its three largest positions and reaffirming strong confidence in CVS’s near-, medium-, and long-term outlook.

AI-generated analysis. Not financial advice.

Positive

• CVS shares delivered an 80% total return since Glenview’s May 2024 purchases
• CVS reported healthy Q1 results and increased annual guidance
• CVS remains a top-three position in Glenview’s portfolio after rebalancing
• Glenview expresses strong confidence in CVS’s near-, medium-, and long-term outlook

Negative

• Glenview reduced its CVS holdings by 3.75 million shares in May 2026

Key Figures

Total return since May 2024: 80% Shares reduced: 3.75 million shares CVS associates: 300,000 +5 more

8 metrics

Total return since May 2024 80% Glenview’s CVS position performance over two years

Shares reduced 3.75 million shares Glenview reduction in CVS holdings after Q1 results

CVS associates 300,000 Employees and associates referenced by Glenview

Price vs 52-week high -5.23% Distance from 52-week high of $98.43 before this news

52-week low $58.50 52-week low level prior to this announcement

Shares represented at meeting 1,142,802,406 shares Quorum at May 14, 2026 annual shareholder meeting

Director grant reference price $97.15 per unit Valuation for May 14, 2026 director equity grants

Market capitalization $122,476,262,199 Market cap before Glenview statement

Market Reality Check

Price: $93.28 Vol: Volume 7,779,964 versus 2...

normal vol

$93.28 Last Close

Volume Volume 7,779,964 versus 20-day average 9,162,221 indicates slightly lighter trading activity. normal

Technical Shares at $93.28, trading above 200-day MA of $77.56 and 5.23% below the $98.43 52-week high.

Peers on Argus

CVS fell 0.96% with peers also down: CI -2.8%, ELV -1.68%, HUM -3.31%, CNC -2.98...

CVS fell 0.96% with peers also down: CI -2.8%, ELV -1.68%, HUM -3.31%, CNC -2.98%, MOH -1.43%, pointing to a broader healthcare plans decline.

Historical Context

5 past events · Latest: May 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 20	Community support update	Positive	+0.1%	Highlighted expanded support and spending with veteran-owned small businesses.
May 18	Digital health strategy	Positive	+0.1%	Released digital literacy study and outlined $20 billion tech investment plans.
May 14	Education partnership	Positive	-1.0%	Launched WGU pre-pharmacy degree program for CVS colleagues nationwide.
May 13	Asset sale approval	Positive	-1.0%	Court approved Omnicare sale to GenieRx, pending regulatory clearances.
May 13	Clinical program update	Positive	+3.1%	MinuteClinic reported strong outcomes in its supervised weight-loss program.

Pattern Detected

Recent operational and strategic updates have often seen mixed price reactions, with some positive news aligning with modest gains and others selling off despite constructive narratives.

Recent Company History

Over the last few weeks, CVS issued several operational updates. Military community support included $292 million in 2025 spending with veteran-owned small businesses. A digital health literacy white paper highlighted a planned $20 billion technology investment. Education and workforce efforts expanded via a new pre-pharmacy program, while Omnicare’s sale to GenieRx advanced portfolio reshaping. MinuteClinic’s weight-loss program reported high engagement and efficacy metrics. Today’s Glenview statement fits into this backdrop of operational initiatives and investor engagement.

Market Pulse Summary

This announcement highlights Glenview’s continued conviction in CVS following an 80% total return si...

Analysis

This announcement highlights Glenview’s continued conviction in CVS following an 80% total return since May 2024, while noting a 3.75 million-share reduction for portfolio diversification. Contextually, CVS trades above its $77.56 200-day MA and modestly below its $98.43 52-week high. Recent news has focused on technology investment, community initiatives, and portfolio reshaping. Investors may watch future large-holder filings, operational execution, and further guidance updates as key indicators.

Key Terms

special purpose vehicle, pharmacy benefit management, prior authorization

3 terms

special purpose vehicle financial

"successful resolution of a special purpose vehicle raised in mid-2024 to invest"

A special purpose vehicle (SPV) is a separate legal entity created to isolate financial risk or hold specific assets, much like a dedicated safe for a particular investment or project. Investors pay attention to SPVs because they can influence how risks and rewards are managed, and sometimes they are used to structure transactions more efficiently or hide certain financial details.

pharmacy benefit management medical

"greater transparency and alignment in pharmacy benefit management, enhanced access"

Pharmacy benefit management is a business that acts like a shopping agent for prescription drugs: it negotiates prices with drug makers, decides which medicines are covered, processes claims, and runs or networks pharmacies on behalf of insurers, employers, and government plans. Investors care because these managers influence drug costs, company revenues and profit margins, and are sensitive to changes in regulations or shifts in how drugs are bought and paid for.

prior authorization regulatory

"improved speed and reduced friction in prior authorization of medical claims"

Prior authorization is a process where a health insurance company requires approval before covering certain medical services or medications. It functions like a pre-approval step, ensuring that the treatment is necessary and appropriate before expenses are paid. For investors, understanding prior authorization is important because delays or denials can impact healthcare costs, provider operations, and the financial stability of related companies.

AI-generated analysis. Not financial advice.

NEW YORK, May 21, 2026 /PRNewswire/ -- Two years ago, we established a concentrated position in shares of CVS Health (NYSE: CVS). Since our purchases in May 2024, CVS shares have generated a total return of 80%, reflecting progress in the long-term cultural and operational turnaround underway at the Company. We rebalanced our position in May 2025 and once again our funds have rebalanced positions in May 2026 including the successful resolution of a special purpose vehicle raised in mid-2024 to invest exclusively in the shares of CVS Health. 

Following healthy Q1 results and increased annual guidance, Glenview reduced its overall holdings by 3.75 million shares consistent with our fund's diversification parameters and to create buying power for further unique opportunities in this volatile macro environment. With this rebalancing, CVS Health remains among our three largest positions, and we have no plans for additional adjustments to our CVS holdings. Our confidence in the near, medium, and long-term outlook for CVS remains strong.

With greater operational intensity, discipline, alignment and focus, CVS Health continues to make a positive impact on the health and well-being of the majority of Americans. We appreciate and applaud the efforts and determination of the 300,000 associates of CVS and commend Management on leading industry innovations to promote fair and simple pharmacy reimbursement, greater transparency and alignment in pharmacy benefit management, enhanced access and affordability of conventional and specialty medications, improved speed and reduced friction in prior authorization of medical claims and enhanced care navigation through Health 100. 

Together we grow.

About Glenview Capital
In its 26th year of operations, Glenview Capital is a long-term investment partnership focused on fundamental investing.

Contact:
Logan Flynn
lflynn@hstrategies.com

View original content:https://www.prnewswire.com/news-releases/glenview-capital-issues-statement-on-cvs-health-302779460.html

SOURCE Glenview Capital

FAQ

What did Glenview Capital announce about its CVS Health (NYSE: CVS) position on May 21, 2026?

Glenview Capital announced it rebalanced its CVS Health position, selling 3.75 million shares while keeping CVS a top-three holding. According to Glenview Capital, CVS has produced an 80% total return since its May 2024 purchases and remains a high-conviction investment.

How has the CVS Health (NYSE: CVS) investment performed for Glenview Capital since May 2024?

Glenview Capital reported an 80% total return on its CVS Health investment since May 2024 purchases. According to Glenview Capital, this performance reflects ongoing cultural and operational progress as CVS executes a long-term turnaround across its healthcare and pharmacy businesses.

Why did Glenview Capital sell 3.75 million CVS Health (NYSE: CVS) shares in May 2026?

Glenview Capital sold 3.75 million CVS shares to rebalance its portfolio and support diversification goals. According to Glenview Capital, the sale also created buying power for new opportunities while CVS remains one of its three largest positions with a strong outlook.

Does Glenview Capital plan further changes to its CVS Health (NYSE: CVS) holdings?

Glenview Capital indicated it has no plans for additional adjustments to its CVS holdings after the May 2026 rebalancing. According to Glenview Capital, CVS remains a top-three position, and its confidence in CVS’s near-, medium-, and long-term prospects remains strong.

How does Glenview Capital view CVS Health’s Q1 results and guidance in 2026?

Glenview Capital described CVS Health’s Q1 results as healthy and noted CVS increased its annual guidance. According to Glenview Capital, these developments supported its decision to maintain CVS as a major holding despite selling 3.75 million shares during portfolio rebalancing.

What strategic themes does Glenview Capital highlight about CVS Health’s business model?

Glenview Capital highlights CVS’s focus on operational intensity, discipline, and healthcare innovation across pharmacy, benefit management, and care navigation. According to Glenview Capital, initiatives include fairer pharmacy reimbursement, more transparent PBM practices, improved prior authorization, and enhanced navigation through the Health 100 program.